Detectability of the Bladder With an Early Prototype of the Bladder Sensor

Urinary Incontinence Clinical Trial

Official title:

An Explorative, Monocentric, Feasibility Study to Evaluate the Detectability of the Bladder in Healthy Subjects by Ultrasound Monitoring With the Early TENA Bladder Sensor Prototype

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04720222
• Other study ID #: ELECTRO
• Secondary ID: P2101NL76062.028
• Status: Completed
• Phase: N/A
• Start date: April 29, 2021
• Est. completion date: October 19, 2021

Study information

• Verified date: November 2021
• Source: Essity Hygiene and Health AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an explorative, monocentric, feasibility study to evaluate the detectability of the bladder in healthy subjects by ultrasound monitoring with the early prototype of a future bladder sensor, which is intended for use for an individual suffering from urinary incontinence.

Description:

The purpose of this clinical investigation with healthy subjects (defined as subjects without urological problems or lower urinary tract symptoms, assured by pre-defined inclusion and exclusion criteria) is to collect raw measurement data of the urinary bladder region of volunteers with the TENA-PROTO1, in multiple postural positions to evaluate the detectability of the bladder in the intended users and to determine the position criteria for the (future) ultrasound sensor on the lower abdomen. Secondarily, this clinical investigation aims to collect data on the adhesive and supportive belt used to fix the transducer assembly to the lower abdomen by the subject. Furthermore, safety of the subjects will be continously documented such as adverse events (AE) and device deficiencies (DD); AEs, Adverse Device Events (ADE), Severe Adverse Events (SAE), Severe Adverse Device effects (SADE), Unanticipated Serious Adverse Device Effects (USADE) and DDs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 91
• Est. completion date: October 19, 2021
• Est. primary completion date: October 19, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 74 Years

Eligibility

Inclusion Criteria:

• Men, women and diverse = 35 and <75 years old

• Capability to understand the subject information and to provide conscious informed consent

• Signed informed consent for study participation and data protection regulations

• All subjects with childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of a Pearl-Index less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices, sexual abstinence or vasectomized partner for at least 4 weeks

• Willingness to conduct a urine pregnancy test for all subjects with childbearing potential

• BMI =18.5 kg/m² and <40 kg/m²

• Capability and willingness to follow the following requirements: protocol, current hygiene concept and laboratory safety

Exclusion Criteria:

• Subjects with urological problems or lower urinary tract symptoms

• Subjects with breached skin, open wounds, sutures or major scar tissue in the suprapubic region.

• Subjects with active implants that can be affected by electromagnetic interference (e.g. pacemaker)

• Subjects with symptoms of constipation or diarrhea

• Subjects who are pregnant or breast feeding

• Known allergies or intolerances to one or several components of the study product

• Alcohol abuse as reported by subject and/ or suspected by investigator that impacts capability to understand the subject information and to provide conscious informed consent in the discretion of the investigator / study personnel

• Drug abuse as reported by subject and/ or suspected by investigator that impacts capability to understand the subject information and to provide conscious informed consent in the discretion of the investigator / study personnel

• Objections of the investigator to the subject's participation in the trial due to medical reasons or any other reason for which the subject should not participate in the opinion of the investigator

• Participation in any clinical investigation with systemic and/or pharmaceutical substances within the last 4 weeks and/or in parallel

• Sponsors, manufacturers or CRO staff

Related Conditions & MeSH terms

• Urinary Incontinence

Intervention

Device:
• TENA-PROTO1
Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device

Locations

Country	Name	City	State
Netherlands	Novioscan - an Essity company	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Essity Hygiene and Health AB

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bladder detectability rate as a function of gender, BMI, age, sensor position, posture and combinations of these variables	Percentage of those, where the bladder was detected in total or regarding different subgroups (BMI, age, sex, postural positions and sensor location ) based on raw measurement data of the urinary bladder region of volunteers with the early prototype of the Bladder Sensor in multiple postural positions to evaluate the detectability of the bladder in the intended users	4 months
Primary	Raw measurement data for the development of an algorithm to determine the bladder filling status	Raw data, that has been assessed by the prototype (TENA-PROTO1) will be used to develop a product specfic algorithm (R&D outcome)	4 months
Secondary	Any adverse event (AE) or device deficiency (DD)	Documentation of AEs, Adverse Device Events (ADE), Severe Adverse Events (SAE), Severe Adverse Device effects (SADE), Unanticipated Serious Adverse Device Effects (USADE) and DDs.	Ongoing documentation after enrolment until end of the measurement day (4 months)
Secondary	Evaluation of the fixation methods and device regarding user needs by the subjects on a score	Descriptive analyses of scores assessed by a questionnaire completed by subjects regarding the adhesive and supportive belt used to fix the transducer assembly to the lower abdomen by the subject during and at the end of the measurements	4 months